Adverum Faces Rocky Road As It Switches Gears From DME To Wet AMD

Gene Therapy Company Calls Off Diabetic Macular Edema Program

 
• By Alaric DeArment

Adverum said it would cease developing ADVM-022 for DME and focus on wet AMD, but the adverse events that prompted the shift could invite further scrutiny in an already competitive market.

Eye
Adverum is shifting the focus of its gene therapy from DME to wet AMD, but it faces a challenging path forward • Source: Shutterstock

More from Clinical Trials

More from R&D